low - Clinical-stage biotech revenue is negligible, so GDP fluctuations have minimal direct impact on operations. However, economic downturns severely affect access to capital markets (equity/debt financing), which is existential given $100M+ annual burn and 4.04 current ratio suggesting 12-18 month runway. Recession-driven risk-off sentiment disproportionately punishes speculative, cash-burning biotechs regardless of clinical progress.

High sensitivity through two channels: (1) Valuation multiples compress as risk-free rates rise (248x P/S reflects discounted future cash flows heavily weighted 5-10 years out, highly sensitive to discount rate changes), and (2) Cost of capital increases for debt financing (2.35 D/E ratio means refinancing risk). Rising rates from current levels would pressure the stock through multiple compression even if clinical progress continues. Fed funds rate changes of 50-100bps can drive 20-30% valuation swings in pre-revenue biotech.

growth/speculative - Attracts biotech-focused hedge funds, venture capital crossover funds, and retail momentum traders betting on binary clinical catalysts. 158% 1-year return and 77% 6-month return reflect speculative positioning rather than fundamental value. Not suitable for value or income investors given negative margins, no dividends, and binary risk profile. Typical holders are willing to accept 50%+ downside risk for 200-500% upside on successful clinical readouts.